Ectopic adrenocorticotropin syndrome

A. Morton

DOI: https://doi.org/10.1111/imj.13602

2017-11-01

Abstract:Ectopic adrenocorticotropin syndrome (EAS) is classically associated with neuroendocrine tumours and small-cell lung cancer (SCLC) but may complicate many more commonmalignancies. Three cases of EAS secondary to cancers not typically associated with this condition are presented. Case 1: A 69-year-old woman with metastatic breast cancer presented with symptomatic hyperglycaemia, cardiac failure and hypokalaemia. Phenotypic features of Cushing syndrome (CS) were absent. Late night salivary cortisol, 24-h urine-free cortisol (24-hUFC) and serum adrenocorticotropin (ACTH) were elevated, consistent with EAS. Spironolactone and metyrapone therapy resulted in the resolution of hypokalaemia and cardiac failure, reduction in insulin requirements and normalisation of urine cortisol levels. Case 2: A 63-year-old previously normotensive woman presented with a painful hypogastric mass, weight loss, severe hypertension and hypokalaemic alkalosis. Further investigation revealed metastatic endometrial adenocarcinoma. Severe hypertension persisted despite four antihypertensive agents. Midnight serum cortisol, 24-hUFC and ACTH were elevated, consistent with EAS. Hypertension and hypokalaemia resolved with spironolactone monotherapy. The patient declined chemotherapy or bilateral adrenalectomy, and ketoconazole caused hepatotoxicity. The patient died 3 months after presentation. Case 3: Six months following surgery for parotid acinic cell carcinoma, a 52-year-old woman presented with myopathy, severe hypertension and hypokalaemic alkalosis. Imaging demonstrated widespread metastatic disease. EAS was confirmed by elevated midnight serum cortisol, 24-hUFC and serum ACTH. The original tumour stained positive for ACTH. Hypertension resolved with perindopril and spironolactone, and urinary cortisol levels fell with ketoconazole therapy. The patient declined bilateral adrenalectomy, proceeding to palliative chemotherapy. Neutropenic sepsis ensued, and the patient died 3 weeks after presentation. EAS may complicate an extensive variety of neoplasms (Table 1). EAS may be underdiagnosed in patients with cancer. Although only 10 cases of EAS have been reported with breast cancer, ACTH peptides were detected in 16.7 % of 150 cases of primary breast cancer. EAS may present with signs of predominant mineralocorticoid excess due to the inability of 11-betahydroxysteroid dehydrogenase-2 to inactivate cortisol at high concentrations; cortisol then acts on the mineralocorticoid receptor. Patients may therefore present with treatment-resistant hypertension and hypokalaemic alkalosis without developing a Cushingoid phenotype. Early diagnosis of EAS is important because of the significant morbidity and mortality associated with the syndrome due to sepsis, thromboembolism, cardiac failure and gastrointestinal haemorrhage. In patients with SCLC and neuroendocrine tumours, the presence of EAS is associated with shortened survival. The optimal treatment of EAS is surgical resection of the primary tumour or successful cytotoxic treatment. Medical therapies for hypercortisolaemia may have limited efficacy and significant toxicity. Laparoscopic bilateral adrenalectomy is the most effective and expedient treatment for hypercortisolaemia in EAS where cure of the primary tumour is not possible. Recently successful percutaneous computed tomography-guided microwave ablation of the adrenal gland has been described. In conclusion, EAS may complicate many neoplasms. The diagnosis should be considered in any patient with a known or suspected cancer presenting with hypokalaemia, resistant hypertension, hyperglycaemia or myopathy irrespective ofwhether phenotypic features of CS are present.